Viewing nowLurucapsule 50mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
Jungheon Pharmaceutical Co., Ltd.

MFDS item code 202000174 · Approved 2020.01.10 · Insurance code 053301100
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medicine is used to treat peripheral and central neuropathic pain in adults. It also helps as an adjunct in patients with epilepsy, whether secondary generalized symptoms are present or not, for partial seizures. Additionally, it is used to treat fibromyalgia, contributing to pain relief. This drug is effective in improving the symptoms of various neurological disorders.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Dosing regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Use is not recommended because sufficient safety and efficacy data are not available. Adolescents aged 12-17 years: Use is not recommended because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, any occurrence of depression or mood changes during use should be reported to a healthcare professional immediately. Do not use this drug if you have an allergy to it or a specific genetic condition causing lactose intolerance. Diabetic patients should be cautious of weight gain and fluctuations in blood sugar, and adjustments to glycemic control medications may be necessary. If severe allergic reactions such as angioedema occur, discontinue use immediately. Elderly patients should be aware of the risk of falls or injuries due to dizziness or drowsiness. Blurry vision or changes in vision may occur; if these symptoms appear, consult a physician. Abrupt discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, and anxiety; thus, it should be gradually reduced according to a professional's guidance. There is a risk of drug abuse; therefore, it should be used more cautiously in individuals with a history of mental illness or substance abuse. Patients with decreased kidney function may require dosage adjustments. Caution is required in patients with severe heart disease. Taking this medication with other central nervous system depressants or alcohol may increase the risk of drowsiness and respiratory depression; caution is advised. During early pregnancy, there may be risks to the fetus, so women who are pregnant or planning to become pregnant should use it only after consulting a physician. If breastfeeding, this medication can be passed into breast milk, so consult with a healthcare provider regarding breastfeeding. Activities requiring concentration, such as driving or operating machinery, should be avoided until symptoms stabilize after taking this medication. In case of overdose, symptoms such as severe drowsiness, confusion, depression, and seizures may occur, and immediate emergency treatment is necessary. This medication should be stored out of reach of children and should not be transferred to another container.
Suicidal impulses, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital edema, upper respiratory tract edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, major congenital malformations, nasopharyngitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, hypersensitivity, euphoria, decreased libido, depersonalization, sexual arousal disorder, restlessness, anxiety, mood instability, emotional lability, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, loss of control, apathy, dizziness, drowsiness, ataxia, motor coordination issues, balance disorders, amnesia, attention disorders, memory disorders, tremors, speech disorders, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech impairment, myoclonus, reflex reduction, motor abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, action tremor, syncope, confusion, hypokinesia, olfactory disturbances, loss of taste, writing impairment, blurred vision, diplopia, indirect vision loss, visual disturbances, visual defects, photophobia, dry eye, eye swelling, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, during vibration, changes in depth perception of the visual field, strabismus, visual brightness, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urine output, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, swelling, gait abnormalities, falling, feeling drunk, sensory disturbances, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased blood creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, state of confusion, depression, agitation, restlessness, seizures, affective disorder, drowsiness, state of confusion, depression, agitation, restlessness, seizures
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 15 to 30 degrees Celsius. This will help maintain the drug's effectiveness for a longer time.
A hard capsule with a dark blue upper part and a white lower part containing a powder that is white to light yellow.
Domestic - 30 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
Jungheon Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.